Sparstolonin B Inhibits Pro-Angiogenic Functions and Blocks Cell Cycle Progression in Endothelial Cells

H. R. Bateman
Q. Liang
D. Fan
V. Rodriguez

Susan M. Lessner
University of South Carolina - Columbia, susan.lessner@uscmed.sc.edu

Follow this and additional works at: https://scholarcommons.sc.edu/eche_facpub

Part of the Cardiovascular System Commons, Cells Commons, Circulatory and Respiratory Physiology Commons, Medical Biochemistry Commons, and the Medical Cell Biology Commons

Publication Info
Published in PLoS ONE, Volume 8, Issue 8, 2013, pages 1-9.
© PLoS ONE, 2013, Public Library of Science Publications

Bateman, H.R., Liang, Q., Fan, D., Rodriguez, V., Lessner, S.M. (2013). Sparstolonin B inhibits pro-angiogenic functions and blocks cell cycle progression in endothelial cells. PLoS ONE, 8(8), 1-9
http://dx.doi.org/10.1371/journal.pone.0070500

This Article is brought to you by the Chemical Engineering, Department of at Scholar Commons. It has been accepted for inclusion in Faculty Publications by an authorized administrator of Scholar Commons. For more information, please contact digres@mailbox.sc.edu.
Sparstolonin B Inhibits Pro-Angiogenic Functions and Blocks Cell Cycle Progression in Endothelial Cells

Henry R. Bateman¹, Qiaoli Liang¹², Daping Fan¹, Vanessa Rodriguez³, Susan M. Lessner¹*  

¹Department of Cell Biology and Anatomy, University of South Carolina, School of Medicine, Columbia, South Carolina, United States of America, ²School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China, ³South Carolina Governor’s School for Science and Mathematics, Hartsville, South Carolina, United States of America

Abstract

Sparstolonin B (SsnB) is a novel bioactive compound isolated from *Sparganium stoloniferum*, an herb historically used in Traditional Chinese Medicine as an anti-tumor agent. Angiogenesis, the process of new capillary formation from existing blood vessels, is dysregulated in many pathological disorders, including diabetic retinopathy, tumor growth, and atherosclerosis. In functional assays, SsnB inhibited endothelial cell tube formation (Matrigel method) and cell migration (Transwell method) in a dose-dependent manner. Microarray experiments with human umbilical vein endothelial cells (HUVECs) and human coronary artery endothelial cells (HCAECs) demonstrated differential expression of several hundred genes in response to SsnB exposure (916 and 356 genes, respectively, with fold change ≥2, p<0.05, unpaired t-test). Microarray data from both cell types showed significant overlap, including genes associated with cell proliferation and cell cycle. Flow cytometric cell cycle analysis of HUVECs treated with SsnB showed an increase of cells in the G1 phase and a decrease of cells in the S phase. Cyclin E2 (CCNE2) and Cell division cycle 6 (CDC6) are regulatory proteins that control cell cycle progression through the G1/S checkpoint. Both CCNE2 and CDC6 were downregulated in the microarray data. Real Time quantitative PCR confirmed that gene expression of CCNE2 and CDC6 in HUVECs was downregulated after SsnB exposure, to 64% and 35% of controls, respectively. The data suggest that SsnB may exert its anti-angiogenic properties in part by downregulating CCNE2 and CDC6, halting progression through the G1/S checkpoint. In the chick chorioallantoic membrane (CAM) assay, SsnB caused significant reduction in capillary length and branching number relative to the vehicle control group. Overall, SsnB caused a significant reduction in angiogenesis (ANOVA, p<0.05), demonstrating its *ex vivo* efficacy.

Introduction

Sparstolonin B (SsnB) is a novel bioactive compound isolated from the plant *Sparganium stoloniferum*, a perennial, aquatic plant grown in North and East China, whose tubers have long been used in Traditional Chinese Medicine (TCM) for the treatment of several inflammatory diseases and as an anti-spasmodic and anti-tumor agent. NMR and X-ray crystallography have identified SsnB as a polyphenol with structural similarities to isocoumarins, a class of compounds that often exhibit anti-coagulant, anti-inflammatory, and anti-tumor properties [1–3]. SsnB may hold potential as a safe, non-toxic pharmaceutical agent for the treatment of several pathological conditions. At concentrations up to 100 μM, SsnB does not exhibit cytotoxic effects on various cell types, including mouse peritoneal macrophages, HUVECs, human aortic smooth muscle cells, and monocytic THP-1 cells [3]. Prior research has shown that SsnB exhibits strong anti-inflammatory effects on mouse and human macrophages by selectively inhibiting the inflammatory responses of macrophages to ligands for Toll-like Receptor (TLR) 2 and TLR4. SsnB has also been shown to suppress downstream signaling pathways after TLR2 and TLR4 activation, including MAPK and NF-κB [3]. These findings suggest that SsnB may be an antagonist to TLR2 and TLR4.

Angiogenesis refers to capillary formation from existing blood vessels. Angiogenesis plays an important role in many physiological events in the body, including wound healing, embryogenesis, and female reproductive processes [4,5]. During these normal processes, angiogenesis is highly regulated. Unregulated, excessive angiogenesis contributes to many pathologies, such as rheumatoid arthritis, psoriasis, retinopathy, and tumor growth and metastasis [6]. Inhibiting pathological angiogenesis may prove to be an effective therapy for these angiogenesis-related diseases.

Angiogenesis is a complex process that occurs in several stages and involves interactions between cells, soluble factors, and extracellular matrix molecules. Endothelial cells play a key role in angiogenesis. Endothelial cells can secrete proteolytic enzymes which break down the basement membrane of an existing blood vessel, allowing the cells to invade the surrounding tissues, migrate in response to an angiogenic stimulus, and proliferate. Growth
Sparstolonin B Inhibits Pro-Angiogenic Functions

Factors and other soluble proteins in the ECM often facilitate and regulate this process, including vascular endothelial growth factor (VEGF). The endothelial cells form a new lumen, start to secrete extracellular matrix molecules, and ultimately form a new capillary [7–9]. Mural cells are also recruited to the site and play an important role in angiogenesis. Angiogenesis may be inhibited at any of these key steps [10]. Targeting endothelial cell proliferation, cell migration, and chemotaxis have shown potential in angiogenesis inhibition.

In the present study, we demonstrate that SsnB inhibits endothelial cell functions related to angiogenesis in several in vitro functional assays, and we also show that SsnB inhibits angiogenesis in an ex vivo assay. The data suggests the potential of SsnB as an anti-angiogenic agent by showing inhibition of human endothelial cell tube formation and migration. We have also examined the effects of SsnB on endothelial cell gene expression, focusing in particular on pathways related to angiogenesis. In addition, our data show that SsnB arrests endothelial cell division in the G1 phase and downregulates the cell cycle proteins cdc6 and cyclin E2. Furthermore, SsnB caused a significant reduction in blood vessel length and branching number in the chick chorioallantoic membrane assay. Overall, these findings add anti-angiogenic and cytostatic properties to the list of diverse effects exhibited by SsnB.

### Experimental Procedures

#### Materials

Sparstolonin B was purified from the plant *Sparganium stoloniferum* according to previously published methods [3]. The purity of SsnB was determined to be greater than 99% by HPLC, and a stability test was utilized to ensure that samples were consistently >99% pure.

- **Cell Culture** – Human coronary artery endothelial cells (HCAECs), human umbilical vein endothelial cells (HUVECs), and human cardiac microvascular endothelial cells (HMVECs) were obtained from Lonza (Hopkinton, MA) and cultured on polystyrene, tissue culture-treated petri plates (100×20 mm) coated with 0.1% gelatin. HUVECs, HCAECs, and HMVECs were cultured in endothelial cell medium supplemented with 10% fetal bovine serum (FBS) and endothelial cell mitogen/growth supplement (Biomedical Technologies, Stoughton, MA). The endothelial cell medium was replaced every 2–3 days, and the cells were passaged after complete confluence was reached. Confluent plates were trypsinized and split, and the cells were cultured until the fourth passage was reached.

- **Matrigel Tube Formation Assay**

To initially determine if SsnB inhibited pro-angiogenic cell functions, a tube formation assay with Matrigel was performed. Growth factor reduced Matrigel (BD Biosciences, Bedford, MA) was added to the wells of a 96 well polystyrene culture plate and incubated at 37°C for 30 minutes. Cells (HUVECs, HCAECs, or HMVECs at passage 2 to 4) were added to each well to reach a final number of 20,000 cells per well. SsnB was added to the wells at a concentration of 1, 10, or 100 μM. Endothelial cell medium with DMSO (0.1%) was used as a vehicle control. Each group contained 8 replicates. The plates were placed in an incubator for 4 h. During the incubation, the endothelial cells formed elongated structures called cords, also known as tubes. After 4 h, neutral buffered formalin was added to fix the cells. Pictures of three non-overlapping fields were taken from each well. The lengths of single cell endothelial cords were measured with Image-Pro Plus (Media Cybernetics, Silver Spring, MD), and the sum of tube lengths for each well was determined. The average total length and standard deviation for each group were determined, and the appropriate statistical tests (ANOVA and Newman-Keuls) were completed. The tube formation assay was replicated three times for both HUVECs and HCAECs. The assay was also repeated with cardiac HMVECs.

- **Cell Viability**

A Live/Dead assay (Invitrogen, Eugene, OR) was utilized to investigate the effect of SsnB on cell viability. The Matrigel tube formation experiment was repeated with HUVECs in chamber slides at a concentration of 20,000 cells per well. The cells were treated with SsnB (1, 10, or 100 μM) or Vehicle Control (0.1% DMSO) as described above. After four hours of incubation, the slides were removed. A chamber slide containing HUVECs treated with 70% methanol for 30 minutes was used as a control for dead cell staining. The slides were aspirated and washed with PBS, and EthD-1 and calcein AM were added to each well. The plates were incubated in the dark, and images were taken with a light microscope at 10X magnification.

- **Transwell Insert Cell Migration Assay**

The cell invasion assay was performed with a Transwell insert system (6.5 mm diameter inserts with 8.0 μm pores in a polycarbonate membrane situated in wells of 24 well polystyrene, tissue culture-treated plates, Corning Incorporated, Corning, NY). The Transwell inserts were coated with 0.1% gelatin for 30 min and incubated in low serum medium for 1 h. Cultured HUVECs were trypsinized and then resuspended in low serum medium (0.5% fetal bovine serum without endothelial cell mitogen), and added at 50,000 cells per insert. The cells were allowed to adhere to the inserts for 30 min. Next, various concentrations of SsnB (0.0001, 0.001, 0.01, 0.1, 1, 10, and 100 μM) or vehicle control (0.1% DMSO) were added to the Transwell inserts. After 30 min, the medium in the lower chamber for the experimental groups was replaced with low serum medium containing 10 ng/ml VEGF, establishing a chemoattractant gradient between the top insert and lower chamber. For the negative control group, the medium was replaced with low serum medium (0.5% fetal bovine serum). The plates were incubated for 8 h at 37°C. During the incubation, the cells migrated through the pores of the Transwell insert towards the lower chamber. At the end of this period, cells on the upper side of the insert were removed, and migrated cells on the bottom side were fixed in formalin and stained with Hoechst dye (a fluorescent nuclear stain). The filter inserts were removed from the wells and mounted on glass slides. Cells were counted from four random fields observed with a 10X objective lens. The cell migration experiments were repeated three times at high SsnB concentrations (0.1, 1, 10, 100 μM) and one time at low SsnB concentrations (0.0001, 0.001, 0.01, 0.1 μM) for HUVECs.

- **Cell Cycle Analysis**

Cell cycle analysis was performed using propidium iodide staining and flow cytometry. HUVECs (approximately 75% confluent) cultured in 6 well polystyrene culture plates coated with 0.1% gelatin were serum starved for 24 hours in low serum medium containing 0.5% fetal bovine serum and no endothelial cell mitogen to synchronize the cells in the G0/G1 phase. After 24 hours, the low serum medium was replaced with treatments of either 100 μM SsnB or vehicle control (0.1% DMSO) diluted in complete growth medium (10% fetal bovine serum with endothelial cell mitogen) in triplicate. The treated cells were incubated for 24, 30, and 36 hours. After incubation, the cells were trypsinized, transferred to 5 ml polystyrene round bottom tubes (12×75 mm), and centrifuged. The medium was aspirated, and the cells were...
washed with PBS. After fixing the cells with ice-cold 70% ethanol for 15 min, the cells were centrifuged and stained with propidium iodide for 30 min. The samples were then analyzed with a flow cytometer (Beckman Coulter FC500). The unstained and stained cell groups were used to calibrate the settings on the flow cytometer. The data were collected and analyzed with ModFit software.

**Microarray Analysis**

Confluent plates (100×20 mm polystyrene, tissue culture-treated petri plates coated with 0.1% gelatin, 75% confluent) of HUVECs and HCAECs (four plates for HUVECs, n = 2, and six plates for HCAECs, n = 3) were chosen for the microarray experiments. Half of the plates received complete growth medium (10% fetal bovine serum with endothelial mitogen) containing vehicle control (0.1% DMSO), and the remaining plates received complete growth medium containing 100 µM SsnB. The plates were incubated for 24 h to allow SsnB to have an effect on cellular gene expression. Following incubation, RNA isolation was completed with the RNeasy Mini kit from Qiagen. The cells were lysed, and RNA was isolated by using the RNeasy spin columns and following the protocol provided by Qiagen. Purified RNA was sent to the Medical University of South Carolina Proteogenomics Facility for microarray analysis. The GeneChip Human Genome U133 Plus 2.0 Array was utilized to track changes in gene expression due to SsnB treatment. Complete data was uploaded to the NCBI Gene Expression Omnibus database (accession number GSE44598).

**Real Time RT-PCR**

After a careful analysis of the microarray data, key genes (CDC6, CCNE2, KITLG, ALDH3A1, CCNB1, CDC2, HMMR, DIAPH3, ANLN, and CDKN3) were chosen for quantitative real-time PCR (qRT-PCR) to verify the gene expression results. HCAECs and HUVECs were exposed to SsnB or vehicle control for 24 h (as previously described in the microarray section). For RT-PCR, RNA was isolated from the cells with the RNeasy Mini kit as described previously. After forward and reverse primer kits (Qiagen, Valencia, CA) were selected, the RNA was amplified. The one-step RT-PCR reactions were completed on the BioRad iCycler thermal cycler system in the Instrumentation Resource Facility at the USC School of Medicine. The expression levels were normalized, and RNA levels were quantified.

**Data Analysis**

Microarray data analysis, including data normalization (robust multi-array average), identification of differentially expressed genes (comparative analyses with dChip software), and heat map construction, was carried out to determine how SsnB affects gene expression and affected pathways (n = 2 for HUVECs and n = 3 for HCAECs). After a careful analysis of the microarray data, several key genes were chosen for qRT-PCR to verify the gene expression results. The genes were chosen based on the following criteria: fold change ≥2, p < 0.05, unpaired t-test with a false discovery rate approximating 0%, appearing in both data sets (HUVECs and HCAECs), and gene function relating to cell proliferation and/or angiogenesis. For qRT-PCR, the expression levels were normalized to the housekeeping gene GAPDH, and RNA levels were compared between groups with the $\Delta\Delta C_t$ method.
SsnB arrests endothelial cells in the G1 phase of the cell cycle

Figure 3 depicts representative results from the cell cycle experiments. In comparison to vehicle controls, flow cytometric cell cycle analysis of HUVECs treated with SsnB showed an increase of cells in the G1 phase and a decrease of cells in the S phase after 24, 30, and 36 hours of treatment. In untreated cells, the percentage of cells in S phase decreased and the percentage in G2/M increased from 24 to 36 hours after addition of growth medium, as expected once cells begin to re-enter and move through the cell cycle. Overall, these results imply that endothelial cells are being arrested in the G0/G1 phase, suggesting an inhibition of cell proliferation, an important step in angiogenesis.

SsnB changes the expression of genes associated with cell cycle and cell proliferation

Microarray experiments demonstrated differential expression of several hundred genes in response to SsnB exposure (916 genes for HUVECs and 356 genes for HCAECs, fold change $\geq 2$, p<0.05, unpaired t-test with a false discovery rate approximating 0%).

Table S1 and Table S2 present the results of the gene function enrichment analysis for HUVECs and HCAECs, respectively. Overall, microarray data from both cell types showed significant overlap, including genes in pathways associated with cell proliferation, cytoskeleton, chemotaxis, and cell cycle, all areas implicated in angiogenesis. These results are consistent with the data obtained from the cell migration and cell cycle functional studies. From this microarray study, it is clear that SsnB regulates genes involved in angiogenic processes in HUVECs and HCAECs.

Real Time RT-PCR

Following microarray data analysis, key genes (listed in Table 1) were chosen for verification with real time RT-PCR. Cyclin E2 (CCNE2) and Cell division cycle 6 (CDC6) are regulatory proteins that control cell cycle progression through the G1/S checkpoint. Both CCNE2 and CDC6 were downregulated in the microarray data. qRT-PCR confirmed that gene expression of CCNE2 and CDC6 was downregulated after SsnB exposure to 64% and 35% of controls, respectively, for HUVECs and to 57% and 14% of controls, respectively, for HCAECs. Kit-Ligand (KITLG), also
known as stem cell factor, is a protein involved in the differentiation and growth of stem cells. Aldehyde dehydrogenase 3 family, member A1 (ALDH3A1) is a protein involved in the aryl hydrocarbon receptor pathway. These genes were chosen for further study because they were highly upregulated by SsnB treatment in the microarray data set. In HUVECs, qRT-PCR analysis demonstrated that KITLG and ALDH3A1 expression was upregulated to 400% and 1280% of controls, respectively. In HCAECs, KITLG and ALDH3A1 expression was upregulated to 260% and 4620% of controls, respectively. The microarray data was supported in both data sets.

SsnB inhibits ex vivo angiogenesis in the CAM assay

The results from the CAM assay are depicted in Figure 4. Overall, SsnB treatment resulted in a significant decrease in normalized blood vessel length compared to the vehicle control group (ANOVA, p<0.05). In addition to reducing total blood vessel length, SsnB treatment also resulted in a significant decrease in the normalized branch number. Compared to the vehicle control, SsnB decreased the number of points where blood vessels branched into two or more separate vessels. Representative images of the CAM from the SsnB and vehicle control groups after two days of treatment are shown in figure 4. The methylcellulose discs released SsnB or vehicle control and were still present at the end of the experiment, as complete biodegradation did not occur. The transparency of the methylcellulose discs allowed easy imaging of the vascular network underneath the discs. Images were taken of regions of the CAM that received methylcellulose discs as well as regions that did not receive discs. For each embryo, the blood vessel length and branch number were measured for both treated and non-treated areas. A normalized value was calculated by

**Figure 2. SsnB inhibits endothelial cell migration.** A. Migrated cells as a function of SsnB concentration (0.1 to 100 μM). B. Migrated cells as a function of SsnB concentration (0.0001 to 0.1 μM) shows a dose-dependent response. *p<0.05 vs. vehicle control, Newman-Keuls test. C. Representative micrographs demonstrating cell migration (left – vehicle control, center – negative control, right – 100 μM SsnB).

doi:10.1371/journal.pone.0070500.g002
dividing the treated areas by the non-treated areas. This approach allowed us to compensate for natural variations in vascular density among embryos that normally occur even in the absence of angiogenic inhibitors or stimulators. Overall, the SsnB-treated group showed fewer blood vessels, reduced vessel lengths, and fewer branches. The methylcellulose discs with SsnB not only inhibited angiogenesis in the area underneath the disc, but also demonstrated inhibition in the immediate area surrounding the discs. Compared to the SsnB group, the vehicle control group exhibited greater vessel lengths, more numerous vessels, and more
vascular branching. In addition, SsnB had no effect on the viability or morphology of the embryos relative to the vehicle control.

Discussion

Pathological angiogenesis is associated with many disorders, including rheumatoid arthritis, diabetic retinopathy, and psoriasis. Recent research has shown that inhibiting angiogenesis may prove to be an effective therapeutic option in treating these disorders. In the present study, potential anti-angiogenic effects of SsnB were demonstrated in the ex vivo CAM assay and in several in vitro functional assays with endothelial cells, including the Matrigel tube formation assay and the Transwell insert cell migration assay. SsnB was also shown to arrest endothelial cells in the G1 phase of the cell cycle. The cellular functions tested in these assays represent key steps in angiogenesis that are inhibited by SsnB, including cell proliferation, cell migration, and chemotaxis. To further investigate the mechanism of action for SsnB, we utilized microarray analysis to examine how SsnB affected gene expression in endothelial cells. After SsnB exposure, genes associated with cell proliferation, cell cycle, chemotaxis, and the cytoskeleton were differentially regulated in both HUVECs and HCAECs. Our data suggest that SsnB alters gene expression in these pro-angiogenic pathways.

Targeting endothelial cell proliferation has shown potential in the area of angiogenesis inhibition. Endothelial cell proliferation may be inhibited in numerous ways, including the downregulation of cell cycle regulatory proteins [10]. Cyclins and cyclin dependent kinases are regulatory proteins that control progression through the cell cycle by regulating specific cell cycle checkpoints. Cyclins help activate cyclin dependent kinases, which phosphorylate downstream proteins that allow cells to progress through these checkpoints. Cyclin E2 (CCNE2) and Cell division cycle 6 (CDC6) are regulatory proteins that control progression through the G1/S checkpoint. CDC6 regulates DNA replication, and cyclin E2 activates cyclin-dependent kinase 2 [11,12]. Downregulation of CCNE2 and CDC6 will trap cells at the G1/S checkpoint and prevent endothelial cells from entering the final stages of cell division. Table 1 demonstrates that CCNE2 and CDC6 were both downregulated by SsnB treatment. Our data show that SsnB affects the gene expression of additional cell cycle regulatory proteins, including cyclin B1 (CCNB1) and cyclin dependent kinase 1 (CDC2). CCNB1 and CDC2 are regulatory proteins that control progression through the G2/M checkpoint. Downregulation of CCNB1 and CDC2 will trap cells at the G2/M checkpoint and prevent endothelial cells from entering the final stages of cell division. Table 1 demonstrates that CCNB1 and CDC2 were both downregulated by SsnB. In addition to preventing cell progression through the G1 checkpoint, SsnB may also prevent progression through the G2/M checkpoint by downregulating these additional cell cycle proteins [13–16].

| Gene    | Microarray Value | Microarray p-value | Microarray Value | Microarray p-value |
|---------|-----------------|-------------------|-----------------|-------------------|
| CCNE2   | 0.64            | 0.24              | 0.01814         | 0.00180           |
| CDC2    | 0.14            | 0.08              | 0.00440         | 0.00004           |
| CDC6    | 0.35            | 0.23              | 0.01527         | 0.00185           |
| CCNB1   | 0.40            | 0.19              | 0.02304         | 0.00003           |
| CDK5    | 0.18            | 0.19              | 0.01471         | 0.00018           |

The comparison of RT-PCR and microarray results is shown in Table 1.

| Gene    | 2ΔΔCt Value | Microarray Value | Microarray p-value | 2ΔΔCt Value | Microarray Value | Microarray p-value |
|---------|-------------|-----------------|-------------------|-------------|-----------------|-------------------|
| KITLG   | 4.0         | 6.2             | 0.02795           | 2.6         | 2.1             | 0.00010           |
| ALDH3A1 | 12.8        | 7.7             | 0.00609           | 46.2        | 8.8             | 0.00001           |
| HMMR    | 0.24        | 0.11            | 0.03073           | 0.062       | 0.20            | 0.00006           |
| DIAPH3  | 0.19        | 0.34            | 0.03248           | 0.26        | 0.38            | 0.00019           |
| ANLN    | 0.20        | 0.09            | 0.00900           | 0.13        | 0.11            | 0.000001          |
| CDKN3   | 0.18        | 0.19            | 0.01471           | 0.22        | 0.18            | 0.00018           |
| CCNB1   | 0.40        | 0.19            | 0.02304           | 0.13        | 0.16            | 0.00003           |
| CDC2    | 0.14        | 0.08            | 0.00440           | 0.17        | 0.20            | 0.00004           |
| CDC6    | 0.35        | 0.23            | 0.01527           | 0.14        | 0.18            | 0.00018           |
| CCNE2   | 0.64        | 0.24            | 0.01814           | 0.57        | 0.38            | 0.00180           |

Table 1. Comparison of RT-PCR and Microarray Results.

The fold expression change vs. vehicle control.

Our data show that SsnB affects the gene expression of additional cell cycle regulatory proteins, including cyclin B1 (CCNB1) and cyclin dependent kinase 1 (CDC2), CCNB1 and CDC2 are regulatory proteins that control progression through the G2/M checkpoint. Downregulation of CCNB1 and CDC2 will trap cells at the G2/M checkpoint and prevent endothelial cells from entering the final stages of cell division. Table 1 demonstrates that CCNB1 and CDC2 were both downregulated by SsnB. In addition to preventing cell progression through the G1 checkpoint, SsnB may also prevent progression through the G2/M checkpoint by downregulating these additional cell cycle proteins [13–16]. This effect is less readily seen due to blockage at the G1 checkpoint in synchronized cells.

Sparganium stoloniferum has long been used in Traditional Chinese Medicine for the treatment of cancer and seizures. Major chemical components from the stem and rhizome, including flavonoids, saponins, and phenylpropanoids, are responsible for these therapeutic effects [17]. Anti-tumor agents often exhibit anti-angiogenic effects, among other cancer suppressing properties. Inhibiting angiogenesis cuts tumors off from the vasculature, limiting growth and metastasis [18]. Previously published research has shown that extracts derived from Sparganium stoloniferum have demonstrated potent anti-cancer effects. Isolated chemical compounds from this herb, including a sucrose ester, a phenylpropanoid glycoside, and a phenylpropanoid glycoside, demonstrated anti-tumor activities [2,19]. In addition, the polyphenolic structure of SsnB also reveals much about its potential therapeutic effects. Many plant-derived polyphenols have demonstrated anti-inflammatory and anti-angiogenic properties. Quercetin and resveratrol, both polyphenols isolated from red wine, have demonstrated anti-inflammatory and anti-angiogenic properties. In addition, oleuropein and hydroxytyrosol, both derived from virgin olive oil, reduce angiogenesis by inhibiting matrix metalloproteinase-9 (MMP-9) and cyclooxygenase-2 (COX-2) [20]. Emodin, another plant-derived polyphenol similar to SsnB, has also been shown to inhibit angiogenesis by targeting endothelial cell proliferation [21]. Emodin causes a downregulation of CCNB1 and CDC2 and a cell cycle arrest at the G2/M phase [22].
In addition to its effects on the cell cycle and cell proliferation, SsnB also affects other key steps of angiogenesis, including cell migration and chemotaxis. The microarray data for both HUVECs and HCAECs demonstrates an enrichment of genes associated with both pathways, including diaphanous homolog 3 (DIAPH3), hyaluronan-mediated motility receptor (HMMR), and anillin (ANLN), an actin binding protein. Furthermore, it is also important to investigate potential upstream pathways that lead to the alterations in gene expression seen in the microarray data. Previously published data have shown that SsnB can suppress the NF-κB pathway, and prior studies have demonstrated a link between NF-κB signaling and expression of cell cycle proteins. Genes for these regulatory proteins, such as CCNE2, CDC6, CCNB1, and CDC2, contain binding sites for NF-κB. SsnB may suppress the NF-κB pathway and cause a subsequent downregulation of the cell cycle regulatory proteins CCNE2 and CDC6. SsnB has also been shown to inhibit the MAPK pathways, including JNK, ERK, and p38 signaling, which all affect gene expression and cell proliferation [23–27]. We need to explore

**Figure 4. SsnB inhibits ex vivo angiogenesis in the CAM assay.**

A. 100 μM SsnB decreased normalized total blood vessel length. B. 100 μM SsnB decreased normalized branching number. *p<0.05 vs. vehicle control, Newman-Keuls test. C. Representative micrographs demonstrating blood vessels in the CAM assay (left – vehicle control, right – 100 μM SsnB, circles show approximate position of methylcellulose discs).

doi:10.1371/journal.pone.0070500.g004
these relationships as potential mechanisms of angiogenesis inhibition.

Furthermore, the CAM assay allowed us to examine the effects of SsnB in an 	extit{ex vivo} system involving additional cell types beyond endothelial cells. Multiple cell types are involved in angiogenesis, including endothelial cells and supporting cells, such as pericytes, smooth muscle cells, macrophages, and myofibroblasts. Since our initial 	extit{in vitro} experiments only involved endothelial cells, we utilized the CAM assay to address the multicellular nature of angiogenesis. We are particularly interested in how SsnB affects macrophages. In the CAM assay, SsnB inhibited blood vessel branching. It has been demonstrated that macrophage production of matrix metalloproteinase-9 (MMP-9) plays an important role in vascular branching during neovascularization [28]. Prior research has shown that SsnB blocks TLR-2 and TLR-4-mediated inflammation in human and murine macrophages[3]. Furthermore, TLR signaling activates MMP production in macrophages [29]. We hypothesize that SsnB blocks TLR signaling and subsequently inhibits macrophage MMP-9 production required for blood vessel branching. Additional experiments could examine this relationship between SsnB, TLR signaling, macrophage production of MMP-9, and vascular branching.

Our current study with HUVECs and HCAECs demonstrates that SsnB inhibits angiogenic processes in functional assays, including the Matrigel tube assay and the Transwell insert cell migration assay, and that it downregulates multiple genes involved in pro-angiogenic pathways as shown by microarray analysis. We have also shown that SsnB inhibits 	extit{ex vivo} angiogenesis in the CAM assay. Future work with SsnB will reveal more about its mechanism of action, including cytoskeletal changes and possible binding sites. Overall, SsnB has proven to be a powerful bioactive compound with a multitude of useful therapeutic effects, including anti-angiogenesis and anti-inflammation.

**Supporting Information**

Figure S1 SsnB inhibits endothelial cell tube formation on Matrigel. Total tube length as a function of SsnB concentration in HMEVCs, *p*<0.05 vs. vehicle control, Newman-Keuls test. (TIF)

Table S1 Gene function enrichment analysis for HUVECs in response to SsnB treatment.

Table S2 Gene function enrichment analysis for HCAECs in response to SsnB treatment.

**Acknowledgments**

We thank Dr. Jeremy Barth of the Proteogenomics Facility at the Medical University of South Carolina for assistance with the microarray analysis. We would also like to acknowledge Dr. Richard Goodvin and Dr. Jay Potts from the School of Medicine at the University of South Carolina for assistance with the CAM assay.

**Author Contributions**

Conceived and designed the experiments: HB QL DF VR SL. Performed the experiments: HB VR. Analyzed the data: HB DF VR SL. Contributed reagents/materials/analysis tools: HB QL DF VR SL. Wrote the paper: HB QL DF VR SL.

**References**

1. Qui C, Xu X, Zhu H (2008) The studies on the anti-inflammatory and analgesic effects of SLW. Pharmacology and Clinics of Chinese Materia Medica 14: 7–10.
2. Xiong Y, Deng KZ, Guo YQ, Gao WY, Zhang TJ (2009) New chemical constituents from the rhizomes of Sparganium stoloniferum. Arch Pharm Res 32: 717–720.
3. Liang Q, Wu Q, Jiang J, Duan J, Wang C, et al. (2011) Characterization of sparstolonin B, a Chinese herb-derived compound, as a selective Toll-like receptor antagonist with potent anti-inflammatory properties. J Biol Chem 286: 26470–26479.
4. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182–1186.
5. Risau W (1997) Mechanisms of angiogenesis. Nature 389: 671–674.
6. Staton CA, Reed MW, Brown NJ (2009) A critical analysis of current in vitro and in vivo angiogenesis assays. Int J Exp Pathol 90: 195–221.
7. Bussolino F, Mantovani A, Persico G (1997) Molecular mechanisms of blood vessel formation. Trends Biochem Sci 22: 251–256.
8. Carmeliet P (2003) Angiogenesis in health and disease. Nat Med 9: 347–354.
9. Liekens S, De Clercq E, Neyts J (2001) Angiogenesis: regulators and clinical applications. Biochem Pharmacol 61: 253–270.
10. Pandya NM, Dhalla NS, Santani DD (2006) Angiogenesis-a new target for future therapy. Vascul Pharmacol 48: 265–274.
11. Wu Z, Cho H, Hampton GM, Theodoru D (2009) Cdc6 and cyclin E2 are PTEN-regulated genes associated with human prostate cancer metastasis. Neoplasia 11: 66–76.
12. Borland LR, Mendrez J (2008) CDK6: from DNA replication to cell cycle checkpoints and oncogenesis. Carcinogenesis 29: 237–243.
13. Nigg EA (2001) Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol 2: 21–32.
14. Sullivan M, Morgan DO (2007) Finishing mitosis, one step at a time. Nat Rev Mol Cell Biol 8: 894–903.
15. Tassan JP, Schulte SJ, Bartek J, Nigg EA (1994) Cell cycle analysis of the activity, subcellular localization, and subunit composition of human CDK-activating kinase. J Cell Biol 127: 467–478.
16. O’Farrell PH (2001) Triggering the all-or-nothing switch into mitosis. Trends Cell Biol 11: 512–519.
17. Maxwell PH, Wiesen MC, Chang GW, Clifford SC, Vaux EC, et al. (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis [see comments]. Nature 399: 271–275.
18. Meng H, Xing G, Sun R, Zhao F, Lei H, et al. (2010) Potent angiogenesis inhibition by the particulate form of fallernene derivatives. ACS Nano 4: 2773–2783.
19. Rohde LE, Lee RT (2003) Pathophysiology of atherosclerotic plaque development and rupture: an overview. Semin Vasc Med 3: 347–354.
20. Scoditti E, Calabriso N, Massaro M, Pellegrino M, Storelli C, et al. (2012) Mediterranean diet polyphenols reduce inflammatory angiogenesis through MMP-9 and COX-2 inhibition in human vascular endothelial cells: a potentially protective mechanism in atherosclerotic vascular disease and cancer. Arch Biochem Biophys 527: 81–89.
21. Kwak HJ, Park MJ, Park CM, Moon SI, Yoo DH, et al. (2006) Emodin inhibits vascular endothelial growth factor-A-induced angiogenesis by blocking receptor-2 (KDR/Flk-1) phosphorylation. Int J Cancer 118: 2711–2720.
22. Wang XH, Wu SY, Zhen YS (2004) Inhibitory effects of emodin on angiogenesis. Yao Xue Xue Bao 39: 254–258.
23. Hsu WH, Lee BH, Pan TM (2010) Red mold dioscorea-induced G2/M arrest and apoptosis in human oral cancer cells. J Sci Food Agric 90: 2709–2715.
24. Cade K, Wang Y, Chou HJ, Hsuan SL, Zhang H, et al. (2007) Regulation of the G2/M cell cycle progression by the ERK5- NF-kappaB signaling pathway. J Cell Biol 177: 253–264.
25. Liu F, Li X, Wang C, Cai X, Du Z, et al. (2009) Downregulation of p21-activated kinase-1 inhibits the growth of gastric cancer cells involving cyclin B1. Int J Cancer 125: 2511–2519.
26. Wang Q, Zou L, Liu W, Hao W, Tashiro S, et al. (2011) Inhibiting NF-kappaB activation and ROS production are involved in the mechanism of silibinin’s protection against D-galactose-induced senescence. Pharmacol Biochem Behav 98: 140–149.
27. Meteoglu I, Erdogdu IH, Meydan N, Erkus M, Barutca S (2008) NF-kappaB expression correlates with apoptosis and angiogenesis in clear cell renal cell carcinoma tissues. J Exp Clin Cancer Res 27: 53.
28. Johnson C, Sung HJ, Lessner SM, Fini ME, Gaits GS (2004) Matrix metalloproteinase-9 is required for adequate angiogenic revascularization of ischemic tissue: potential role in capillary branching. Circ Res 94: 262–286.
29. Huang B, Zhao J, Unkeless JC, Feng ZH, Xiong H (2008) TLR signaling by tumor and immune cells: a double-edged sword. Oncogene 27: 210–224.